# Live births after vaginal progesterone Cyclogest suppository versus Crinone gel for luteal phase support following cleavage and blastocyst cryopreserved embryo transfer (CET); a retrospective comparative study

## TL;DR

This study compares two progesterone treatments for luteal phase support in frozen embryo transfers and finds no significant difference in pregnancy or live birth rates.

## Contribution

Demonstrates that Cyclogest suppositories and Crinone gel are equally effective for luteal phase support in frozen embryo transfers.

## Key findings

- No significant difference in live birth rates between Cyclogest and Crinone groups.
- Both treatments showed similar clinical and biochemical pregnancy rates.
- Miscarriage rates were not significantly different between the two groups.

## Abstract

To compare the clinical outcomes, including pregnancy rate, live birth rate,
and miscarriage rate between vaginal progesterone Cyclogest suppository and
Crinone vaginal progesterone gel as LPS in frozen-thawed embryo transfer in
Intra-Cytoplasmic Sperm Injection (ICSI) cycles.

In this comparative retrospective chart review, 283 women who had
frozen-thawed embryo transfer were assessed. The patients were divided into
two groups based on the route of progesterone administration used as LPS.
When the endometrial thickness reached ≥8mm, vaginal progesterone
Cyclogest 400 mg/twice daily suppository was administered in one group; in
another group, vaginal progesterone Crinone 8% 90 mg daily was administrated
until a positive pregnancy test was confirmed. This was continued for 10-12
weeks after embryo transfer when fetal heart activity was detected by
ultrasonography.

The patients’ characteristics in the two groups were matched and there was no
significant difference. The biochemical and clinical pregnancy, miscarriage,
and live birth rates were similar-4.7% vs. 2.7%,
p=0.464; 26.1% vs. 23.3%,
p=0.638; 13.3% vs. 9.6%,
p=0.410; 15.6% vs. 16.4%,
p=0.872, respectively; there was no statistically
significant difference between the vaginal progesterone Cyclogest group and
the Crinone progesterone group.

Clinical pregnancy, biochemical pregnancy, miscarriage, and live birth rates
were similar between both groups. Moreover, vaginal progesterone Cyclogest
and Crinone 8% gel are equally effective in providing support during the
luteal phase for both blastocysts and cleavage-stage embryos in CET.